Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MT Newswires on MSN5h
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading
European equities traded in the US as American depositary receipts were treading water late Wednesday morning, edging 0.03% lower to 1,397.50 on the S&P Europe Select ADR Index. From continental ...
gastroenterologyadvisor7h
Encapsulated Rapamycin Fast Tracked for Familial Adenomatous Polyposis
The FDA has granted Fast Track designation to eRapa, an encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis.